US2019328876A1PendingUtilityA1

Selective removal of age-modified cells for treatment of atherosclerosis

59
Assignee: SIWA CORPPriority: Sep 27, 2010Filed: Feb 1, 2019Published: Oct 31, 2019
Est. expirySep 27, 2030(~4.2 yrs left)· nominal 20-yr term from priority
Inventors:Lewis S. Gruber
A61M 2205/057A61P 9/10A61M 2205/058A61M 2202/0429A61K 39/39533A61B 2017/320069C07K 16/44A61K 39/3955A61K 41/0023A61M 1/3687A61M 1/362A61K 41/0028A61N 7/00
59
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method of treating atherosclerosis comprises removing AGE-modified cells from a patient. The AGE-modified cells include erythrocytes, intima cells, endothelial cells, smooth muscle cells, macrophages, and foam cells. A variety of techniques, such as ultrasound and binding with an anti-AGE antibody, may be used to identify and remove the AGE-modified cells.

Claims

exact text as granted — not AI-modified
What is claimed: 
     
         1 - 43 . (canceled) 
     
     
         44 . A method of treating atherosclerosis, comprising removing AGE-modified cells from a patient,
 wherein the AGE-modified cells removed by destruction with ultrasound.   
     
     
         45 . The method of  claim 44 , wherein the ultrasound is applied at a frequency of 1.0-5.0 MHz, 
     
     
         46 . The method of  claim 44 , wherein the ultrasound is applied at a frequency of 3.0-4.0 MHz. 
     
     
         47 . The method of  claim 44 , wherein the ultrasound is applied for 3-60 minutes daily for 1-20 days. 
     
     
         48 . The method of  claim 44 , wherein the AGE-modified cells are erythrocytes. 
     
     
         49 . The method of  claim 44 , wherein the AGE-modified cells comprise at least one cell type selected from the group consisting of intima cells, endothelial cells, smooth muscle cells, macrophages, and foam cells. 
     
     
         50 . The method of  claim 44 , wherein the patient is a mammal. 
     
     
         51 . The method of  claim 44 , wherein the patient is a human. 
     
     
         52 . The method of  claim 44 , wherein the patient has Syndrome X diabetes. 
     
     
         53 . The method of  claim 44 , further comprising testing the patient for removal of AGE-modified cells. 
     
     
         54 . The method of  claim 53 , wherein the testing comprises measuring the levels of glycated hemoglobin A1C. 
     
     
         55 . The method of  claim 44 , wherein the ultrasound is applied at a frequency of 1.0-5.0 MHz,
 the ultrasound is applied for 3-60 minutes daily for 1-20 days,   the AGE-modified cells are erythrocytes, and   the patient is a human.   
     
     
         56 . A method of removing AGE-modified cells from blood, comprising damaging or destroying the AGE-modified cells with ultrasound. 
     
     
         57 . The method of  claim 56 , wherein the ultrasound is applied at a frequency of 1.0-5.0 MHz. 
     
     
         58 . The method of  claim 56 , wherein the ultrasound is applied at a frequency of 3.0-4.0 MHz. 
     
     
         59 . The method of  claim 56 , wherein the ultrasound is applied for 3-60 minutes daily for 1-20 days. 
     
     
         60 . The method of  claim 56 , wherein the AGE-modified cells are erythrocytes. 
     
     
         61 . The method of  claim 56 , wherein the AGE-modified cells are removed ex vivo. 
     
     
         62 . The method of  claim 56 , further comprising testing for removal of AGE-modified cells. 
     
     
         63 . The method of  claim 56 , wherein the ultrasound is applied at a frequency of 1.0-5.0 MHz,
 the ultrasound is applied for 3-60 minutes daily for 1-20 days, and   the AGE-modified cells are erythrocytes.

Join the waitlist — get patent alerts

Track US2019328876A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.